Alexander Hardy is the President and CEO of BioMarin Pharmaceuticals, a leader in biotechnology, since December 1, 2023. He has over 30 years of experience in the global healthcare and biotechnology sectors, most recently serving as CEO of Genentech, a...
Alexander Hardy is the President and CEO of BioMarin Pharmaceuticals, a leader in biotechnology, since December 1, 2023. He has over 30 years of experience in the global healthcare and biotechnology sectors, most recently serving as CEO of Genentech, a Roche company. Hardy's background includes positions like Head of Global Product Strategy and Head of Asia Pacific at Roche Pharma. He's well-educated, holding a BA from the University of Cambridge and an MBA from the University of Michigan. Under his leadership, BioMarin continues to focus on innovative therapies for serious diseases, aligning with Hardy's extensive knowledge in managing biotech organizations. In his first year at BioMarin, he received a total compensation of approximately $1.848 million, which included a significant signing bonus as he transitioned from Genentech. His experience suggests a strong potential to enhance BioMarin's pipeline and drive future growth.